CSL reported encouraging paediatric ANDEMBRY results as it prepares regulatory filings to expand treatment access for hereditary angioedema.
Why Is CSL (ASX:CSL) Expanding ANDEMBRY Into Paediatric Care?
CSL reported encouraging paediatric ANDEMBRY results as it prepares regulatory filings to expand treatment access for hereditary angioedema.